The safety and tolerance of mezlocillin

Publisher Website
Google Scholar
Abstract
Eleven hundred and forty-eight patients treated with mezlocillin were evaluated for adverse reactions. Mezlocillin doses ranged from 39 to 600mg/kg/day (mean, 257 mg/kg/day) and duration of treatment ranged from 1 to 52 days (mean 8.6 days). Fifty per cent of patients were treated for ≤7 days. Eighty-eight patients (7.7%) experienced systemic and 35 patients (3.0%) experienced local adverse reactions. Hypersensitivity, manifest by drug fever, cutaneous reactions, or eosinophilia occurred in 0.3, 1.8%, and 2.2 (3.7% treated >7 days) respectively. Hypokalaemia developed in 0.7% overall and was dose and duration related. Hepatotoxicity occurred in 0.9%, diarrhoea in 0.7%, and leukopenia in 0.2%. No instance of interstitial nephritis, CNS toxicity, or bleeding was noted. In comparative studies with ticarcillin and carbenicillin a similar number and severity of adverse reactions were seen. Although the incidence of certain adverse reactions may be underestimated due to the short duration of therapy, mezlocillin appears to be exceptionally safe and well tolerated.

This publication has 0 references indexed in Scilit: